List view / Grid view

News

Apitope’s Phase II multiple sclerosis trial a success

22 February 2017 | By Niamh Marriott, Digital Editor

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, announces positive results from the Phase IIa clinical study of its lead product candidate, ATX-MS-1467, for the treatment of patients with multiple sclerosis. The Phase IIa, open-label, one arm study evaluated the effects of…

Custom to build £20 million Pharmaceutical Innovation Centre in Brighton

17 February 2017 | By Niamh Marriott, Digital Editor

Custom Pharma Services, the Brighton based CDMO, is pleased to announce the commencement of the building work on its £20 million Pharmaceutical Innovation Centre (PIC) in Moulsecoomb, Brighton. The Custom PIC will house the contract development, clinical and commercial manufacturing teams in a new, purpose built facility. This investment is…